Top Medical News
Paleo diet focuses on high consumption of fats and low consumption of carbohydrates.
Jairia Dela Cruz, Yesterday
High adherence to the palaeolithic diet helps reduce sleep apnoea in menopausal women who are overweight, with the benefit linked to weight loss, according to a secondary analysis of a trial comparing a 2-year intervention of a palaeolithic diet with a low-fat control diet according to the Nordic Nutritional Recommendations.
Use of RAS inhibitors associated with lower cancer risk in T2D
Natalia Reoutova, Yesterday

A real-world study of over 250,000 type 2 diabetes (T2D) patients from Hong Kong has found that use of renin-angiotensin-system inhibitors (RASIs) is independently associated with reduced risk of cancer, including diabetes-related cancers and cancer-specific mortality in diabetes.

Weight, waistline changes influence future breast cancer risk
2 days ago
Changes in weight and waist circumference appear to have a dose-response association with the risk of future breast cancer, such that the greater the gain, the higher the risk, according to a retrospective study.
Pemafibrate superior to conventional fibrates in T2DM
2 days ago
Treatment with pemafibrate in patients with type 2 diabetes mellitus (T2DM) yields more favourable effects on lipid profile, as well renal function, as compared with conventional fibrates, a study has found.
SGLT2 inhibitors potentially protective against dry eye disease
Jairia Dela Cruz, 5 days ago
Type 2 diabetes (T2D) patients on sodium-glucose cotransporter 2 (SGLT2) inhibitors appear to be at lower risk of dry eye disease (DED) compared with their counterparts who are receiving glucagonlike peptide-1 receptor agonists (GLP-1 RAs), as shown in a study.
Moderate exercise, dieting may reduce risk of C-section, gestational diabetes
Stephen Padilla, 26 Sep 2022
Each additional optimal modifiable factor among women with a history of gestational diabetes mellitus (GDM) significantly contributes to a reduction in type 2 diabetes (T2D) risk, suggests a recent study. These associations are also present among individuals who are overweight/obese or are at greater genetic susceptibility to T2D.
Elobixibat affords metabolic benefits in type 2 diabetes
25 Sep 2022
In type 2 diabetes (T2D) patients with constipation, treatment with elobixibat alleviates constipation while improving glucose metabolism and lowering serum low-density lipoprotein cholesterol (LDL-C) and arachidonic acid (AA) levels, according to the results of a single-arm pilot study.
Special Reports
Empagliflozin: A new dawn for heart failure treatment across the ejection fraction spectrum
06 Jun 2022

Initially approved to improve glycaemic control and reduce cardiovascular death in adults with type 2 diabetes (T2D), the SGLT-2* inhibitor empagliflozin reduced hospitalization for heart failure (HFH) or cardiovascular death and delayed renal function decline when added to recommended therapy in patients with heart failure and reduced ejection fraction (HFrEF) in the EMPEROR-Reduced** trial. The EMPEROR-Preserved** trial has now shown that the benefits of empagliflozin extend to patients with heart failure and preserved ejection fraction (HFpEF).

Early and consistent: Breakthrough results in HFpEF similar to HFrEF
14 Jan 2022
HFpEF represents a significant unmet need in CV medicine due to its prevalence, poor prognosis, and the absence of clinically proven therapeutic options. The EMPEROR-Preserved trial demonstrated the continuous clinical benefits in cardiorenal outcomes of empagliflozin in adults with HFpEF, which were consistent with the observations in adults with HFmrEF/ HFpEF in the EMPEROR-reduced trial. The combined results of the EMPEROR trials establish empagliflozin’s efficacy in heart failure regardless of ejection fraction – and if approved, empagliflozin would become the first and only clinically proven therapy to improve outcomes for the full spectrum of the disease. Therefore, empagliflozin offers a new hope for people living with heart failure.
EMPEROR-Preserved: The first successful trial to improve outcomes in HFpEF
18 Nov 2021
Heart failure with preserved ejection fraction (HFpEF) represents a significant unmet medical need. The EMPEROR-Preserved trial aimed to assess the impact of empagliflozin on cardiovascular outcomes in patients with HFpEF. On 27 August 2021, during the hotline session of the 2021 ESC Virtual Congress, the main results of the EMPEROR-Preserved trial were presented by Professor Stefan Anker, principal investigator of the study, and heart failure specialist at Charité Berlin, Germany.
Clinical benefits of flash glucose monitoring with FreeStyle Libre™
15 Sep 2021
Various studies have shown the beneficial effects of the FreeStyle Libre™ flash glucose monitoring system for the continuous monitoring of glucose levels in type 1 and type 2 diabetes (T1D and T2D) patients. While clinical trials have demonstrated a reduced time in hypoglycaemia, fewer hypoglycaemic events per day, and significant reduction in glycated haemoglobin (HbA1c), real-world data have shown improved glycaemic control in these patients.
Optimising glycaemic control with FreeStyle Libre™ for better patient management
15 Sep 2021
The FreeStyle Libre™ flash glucose monitoring system includes a sensor which automatically measures and continuously stores up to 8 hours of glucose readings, allowing patients to monitor their glucose levels without the need for painful finger pricks. Physicians play an important role in reviewing and analysing glucose data that is available through LibreView to support patient management.
Continuous glucose monitoring versus self-monitoring of blood glucose: A healthcare professional’s perspective
26 Aug 2021
Technological advancements have improved glucose monitoring and diabetes care, as well as empowered patients in self-care. The introduction of continuous glucose monitoring systems (CGM), such as the Abbott FreeStyle LibreTM, offers patients an alternative and additional advantages to self-monitoring of blood glucose (SMBG).
Conference Reports
Fezolinetant reduces hot flashes during menopause
Roshini Claire Anthony, 01 Aug 2022

The neurokinin-3 receptor antagonist fezolinetant reduced the frequency and severity of menopause-associated vasomotor symptoms (VMS), according to results of the extension arm of the phase III Skylight 2 trial presented at ENDO 2022.

Timing of liquid LT4 intake doesn’t impact bioavailability
Elvira Manzano, 01 Aug 2022
Bioavailability studies presented at ENDO 2022 showed that patients with hypothyroidism can safely take the liquid formulations of levothyroxine (LT4) 15 or 30 minutes before meals, without having to worry about food effect on bioavailability.
Growth hormone reduces liver fat, fibro-inflammation in obese/overweight adults with NAFLD
Audrey Abella, 27 Jul 2022
In adults with overweight/obesity and nonalcoholic fatty liver disease (NAFLD), daily administration of growth hormone (GH) reduced hepatic steatosis and improved markers of hepatic inflammation and fibrosis, a study has shown.
Empagliflozin shows promise for chronic SIAD-induced hyponatremia
Audrey Abella, 26 Jul 2022
The sodium-glucose cotransporter 2 inhibitor empagliflozin showed potential as a treatment alternative for hyponatremia due to chronic syndrome of inadequate antidiuresis (SIAD), according to a trial presented at ENDO 2022.
10 percent long-term weight loss with lifestyle management, medication in overweight/obese patients
Roshini Claire Anthony, 25 Jul 2022

Individuals who are overweight or obese can achieve an approximately 10 percent weight loss over 3–5 years with the use of anti-obesity medications in addition to lifestyle management, according to a retrospective study presented at ENDO 2022.

Prediabetes may up MI, PCI, CABG risk
Roshini Claire Anthony, 21 Jul 2022

Individuals with prediabetes appear to be at an elevated risk of developing myocardial infarction (MI) as well as requiring coronary interventions, according to a study presented at ENDO 2022.

Testosterone therapy safe for the heart, but some experts disagree
Elvira Manzano, 08 Jul 2022
Testosterone therapy appeared safe for the heart in men with hypogonadism, according to a meta-analysis of 35 placebo-controlled trials presented at ENDO 2022. However, experts have differing opinions on the findings.